Cell And Gene Therapies Are Altering Patient Expectations, Says CGT Catapult CEO
Patients Will Expect Their Condition To Be Taken Away, Rather Than Treated
The Cell and Gene Therapy Catapult was established in 2012 and exists to advance the growth of the UK’s CGT industry, supporting companies in this space throughout product development and beyond. In Vivo caught up with CEO Matthew Durdy, who took over the role from Keith Thompson in 2020, to learn what the first three years of his tenure have taught him and how he sees the future of advanced therapies progressing.
You may also be interested in...
Multiple gene therapies have been approved in the last couple of years, but market access and reimbursement for gene therapies remain challenging – a key theme of the Cell & Gene Meeting on the Mesa.
Health policy researchers have called on the UK government to address cell and gene therapy workforce gaps at a national level, warning that training academies run by “well-funded” pharma firms risk “undermining” and fragmenting the industry as a whole.
Lupin has announced a number of drug approvals in the US, as well as a biosimilar partnership in the Middle East and the launch of a novel fixed-dose triple combination drug in its native Indian market.